



8

IPW

1637

PATENT
DOCKET NO.: 11220/129

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.: 09/879,217

Confirmation No. 6207

Applicant: Danenberg, Kathleen D.

Filed: June 13, 2001

Art Unit: 1637

Examiner: Jeffrey Fredman

For: METHOD OF DETERMINING
DIHYDROPYRIMIDINE DEHYDROGENASE
GENE EXPRESSION

Customer No. 23838

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

REQUEST FOR THE CONSIDERATION OF TIMELY FILED IDS

Sir:

Enclosed is a copy of the Supplemental Information Disclosure Statement timely filed on October 22, 2001. Applicants respectfully request the consideration of this IDS in the above-identified application.

Applicants do not believe any fees are required. The Office is hereby authorized to charge any fees or credit any overpayments under 37 C.F.R. 1.16 or 1.17 to Kenyon & Kenyon Deposit Account No. 11-0600. The Examiner is invited to contact the undersigned at 202-220-4258 to discuss any matter concerning this application.


Respectfully submitted,

KENYON & KENYON

Application No. 09/879,217

Request for the Consideration of Timely Filed IDS filed July 14, 2005

Date: 7/14/05



Teresa A. Lavenue

Reg. No. 47,737

1500 K Street, N.W.

Washington, D.C. 20005

Telephone: (202) 220-4200

Facsimile: (202) 220-4201



The stamp of the Patent Office hereon may be taken as acknowledging the receipt, on the date stamped, of

INVENTOR(S): Kathleen DANENBERG
SERIAL NO.: 09/879,217
FILED: June 13, 2001
TITLE: METHOD FOR DETERMINING DIHYDROPYRIMIDINE
DEHYDROGENASE GENE EXPRESSION
GROUP ART: 1646
EXAMINER: To Be Assigned

The PTO is authorized to charge any fees or credits regarding this filing to Kenyon & Kenyon Deposit Account No. 11-0600.

PAPERS FILED:

1. SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER
37 CFR § 1.97(b)(3).

TAH:jh
DC01 385553v1

10/22/2001

11220/129





PATENT
Docket No. 11220/129

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR(S) : Kathleen DANENBERG
SERIAL NO. : 09/879,217
FILING DATE : June 13, 2001
FOR : METHOD OF DETERMINING DIHYDROPYRIMIDINE
DEHYDROGENASE GENE EXPRESSION
GROUP ART UNIT : 1646
EXAMINER: : To Be Assigned

ASSISTANT COMMISSIONER
FOR PATENTS
Washington, D.C. 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97(b)(3)**

S I R:

Under the provisions of 37 CFR 1.97(b)(3), and in accord with Applicants' duty of disclosure under 37 CFR 1.56, Applicants would like to call the Examiner's attention to the document cited on the attached form PTO-1449. A copy of the reference is attached.

The Examiner is respectfully requested to review, and to mark as considered, the reference listed on the attached form PTO-1449, to make it of record in the present application and to include it in the "References Cited" section of any patent to issue on the present application.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the present application. The Office is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17, or to credit any overpayment, to Deposit Account No. 11-0600.

The Examiner is invited to contact the undersigned at (202) 220-4322 to discuss any matter in this application.

Respectfully submitted,

KENYON & KENYON

Dated: Oct. 22, 2008



Thomas A. Haag, Ph.D.
(Patent Agent, Reg. No. 47,621)

KENYON & KENYON
1500 K Street, N.W.
Suite 700
Washington, D.C. 20005
(202) 220-4200 (phone)
(202) 220-4201 (fax)
DC385477v1



Form 1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 11220/129	SERIAL NO. 09/879,217
	APPLICANT Kathleen DANENBERG	
	FILING DATE June 13, 2001	GROUP 1646

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS/SUBCLASS	FILING DATE*

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Ichikawa, et al, "Expression of Dihydropyrimidine Dehydrogenase (DPD) and Thymidylate Synthase (TS) mRNA in Primary Tumor Predicts the Anti-Tumor Effect in 5-Fluorouracil (FU Based Chemotherapy for Gastrointestinal (GI Cancer", American Association for Cancer Research, Proceedings of the American Association for Cancer Research, 92 nd Annual Meeting, Volume 42, March 2001. Abstract Number 3326.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with M.P.E.P. 609; strike out citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	